Cargando…
Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
Autores principales: | George, Anju, George, Renu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247661/ https://www.ncbi.nlm.nih.gov/pubmed/32477996 http://dx.doi.org/10.4103/idoj.IDOJ_47_19 |
Ejemplares similares
-
Progressive Symmetric Erythrokeratodermia with Overlying Psoriasis as Wolf's Isotopic Phenomenon: A Case Report
por: Ahmed, Ghazal, et al.
Publicado: (2022) -
Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis
por: Dey, Nidhi S., et al.
Publicado: (2021) -
Topical Tretinoin in the Treatment of Nail Psoriasis
por: Grover, Chander, et al.
Publicado: (2022) -
Suppression of IL‐12/IL‐23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon‐γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon‐driven diseases
por: Vincken, Nanette L. A., et al.
Publicado: (2022) -
Improved quality of life of patients with generalized pustular psoriasis in Japan: A cross‐sectional survey
por: Hayama, Koremasa, et al.
Publicado: (2020)